Giorgio Mosconi

Title: The Innovative Contributions of Giorgio Mosconi

Introduction

Giorgio Mosconi is a notable inventor based in Abano Terme, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of non-muscle invasive bladder cancer. His innovative approach combines established compounds with novel delivery methods to enhance therapeutic efficacy.

Latest Patents

Mosconi holds a patent for a pharmaceutical composition titled "Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer." This patent describes a composition that consists of a paclitaxel prodrug associated with pharmacologically acceptable diluents and excipients. The treatment involves intravesical instillations of the prodrug, administered at a single weekly dose of 600 mg or two weekly doses totaling 1,200 mg, over a course of 12 or 6 consecutive weeks. The prodrug is synthesized through an indirect process that links hyaluronic acid with paclitaxel using a spacer, 4-bromobutyric acid.

Career Highlights

Giorgio Mosconi is affiliated with Fidia Farmaceutici S.p.a., a company known for its commitment to innovative pharmaceutical solutions. His work has focused on developing effective treatments that improve patient outcomes in oncology.

Collaborations

Mosconi collaborates with esteemed colleagues such as Daniela Jabes and Carlo Pizzocaro, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Giorgio Mosconi's contributions to pharmaceutical science, particularly in cancer treatment, highlight the importance of innovation in improving healthcare. His patent reflects a significant advancement in therapeutic strategies for bladder cancer, showcasing his dedication to enhancing patient care.